Home » USA Broker Ratings » Gilead Sciences – Consenus Indicates Potential -4.4% Downside

Gilead Sciences – Consenus Indicates Potential -4.4% Downside

Gilead Sciences with ticker code (GILD) now have 24 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 90 and 53 and has a mean target at 74.79. Now with the previous closing price of 78.21 this now indicates there is a potential downside of -4.4%. The day 50 moving average is 73.3 and the 200 moving average now moves to 67.21. The market cap for the company is $97,864m. Company Website: http://www.gilead.com

Gilead Sciences, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; and Zydelig, a kinase inhibitor for the treatment of patients with relapsed chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma. In addition, the company offers Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. Further, it provides its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Additionally, the company focuses to develop product for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. It markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences has collaboration agreements with The Rockefeller University; Novartis AG; Lyndra Therapeutics; Kyverna Therapeutics; Glympse Bio; Renown Institute; Goldfinch Bio; Insitro; Novo Nordisk A/S; Yuhan Corporation; Eisai Co., Ltd.; Galapagos NV; Carna Biosciences Inc.; Nurix Therapeutics; Humanigen; and Kiniksa Pharmaceuticals, Ltd. The company was founded in 1987 and is headquartered in Foster City, California.

Join us on our new LinkedIn page

Follow us on LinkedIn